Circulation Journal
Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease
Cohort study of 351,858 peopleLipoprotein
Papers on elevated Lp
133 papers37 new in 30 days
Monday, March 2
Saturday, February 28
Friday, February 27
Diabetes, Obesity & Metabolism
Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts
Cohort study of 65,547 peopleCoronary artery disease
medRxiv
Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations
Preprint: cohort study of 49,310 peopleLipoprotein
Journal of Clinical Medicine
Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study
Cohort study of 456 peopleLipoprotein
Thursday, February 26
Tuesday, December 16
Wiadomosci Lekarskie
The role of lipoprotein (a) in the development of cerebral atherosclerosis
ReviewMechanisms
Wednesday, December 10
Monday, November 3
AHA Scientific Sessions 2025 Abstract
Impact of Diabetes Mellitus on Cardiovascular Outcomes in Patients with Elevated Lipoprotein(a): A US Retrospective Cohort Analysis
Cohort study of 19,942 peopleAtherosclerotic cardiovascular disease
AHA Scientific Sessions 2025 Abstract
Sex-Specific Association of Lipoprotein(a) Concentrations with Atherosclerotic Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis
Meta-analysis of observational studiesLipoprotein
AHA Scientific Sessions 2025 Abstract
Association Between Elevated Lipoprotein(a) and New-Onset Atrial Fibrillation: A Retrospective Analysis Using the TriNetX Research Network
Cohort study in peopleAtrial fibrillation
AHA Scientific Sessions 2025 Abstract
Reevaluating Lipoprotein(a) Levels and Risk of All-Cause Mortality in the Setting of Primary Prevention: A Retrospective Cohort Study
Cohort study of 42,770 peopleLipoprotein
AHA Scientific Sessions 2025 Abstract
Lipoprotein(a) and Metabolic Syndrome are Associated with Increased Risk of Coronary Heart Disease
Cohort study of 6,664 peopleMetabolic syndrome
AHA Scientific Sessions 2025 Abstract
STX-1200: A Novel CRISPR-CasX based Gene Editing Approach for Potent and Selective Reduction of Lipoprotein(a) in Multiple Preclinical Models
Experiments in miceInterventions
AHA Scientific Sessions 2025 Abstract
Eicosapentaenoic Acid (EPA) Limits Lipoprotein(a) Oxidation and its Related Effects on Endothelial Cell Stress Response Protein Expression
Experiments in human cellsEicosapentaenoic acid
AHA Scientific Sessions 2025 Abstract
Genetic Evidence Suggests Combined Inhibition of Lipoprotein(a) and PCSK9 to Lower Atherosclerotic Cardiovascular Disease Risk.
Mendelian randomization in 450,000 peopleMechanisms
AHA Scientific Sessions 2025 Abstract
Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Risk in Higher versus Lower Risk Individuals: Findings from the ARIC Study
Cohort study of 9,483 peopleLipoprotein
AHA Scientific Sessions 2025 Abstract
Impact of PCSK9 Inhibitors on Mortality and Cardiovascular Events in Statin-Treated ASCVD Patients with Elevated Lipoprotein A: A Retrospective Study
Cohort study of 6,204 peoplePCSK9 inhibitors
AHA Scientific Sessions 2025 Abstract
Association of Lipoprotein(a) and Interleukin-6 with Cardiovascular Risk: the Multi-Ethnic Study of Atherosclerosis and UK Biobank
Cohort study of 26,574 peopleLipoprotein
AHA Scientific Sessions 2025 Abstract
Integrating Lipoprotein(a) and Albuminuria Screening into Cardiovascular Primary Prevention: Early Outcomes from the CardioPrevent Program
Cohort study in peopleScreening
AHA Scientific Sessions 2025 Abstract
Eicosapentaenoic Acid Attenuates Oxidation of Lp(a) and other Atherogenic Lipoproteins by a Potential Scavenging Mechanism
Experiments in human cellsEicosapentaenoic acid
AHA Scientific Sessions 2025 Abstract
Lp(a) Screening in FQHCs: A National Implementation Science Approach
Study of 10 peopleInterventions
AHA Scientific Sessions 2025 Abstract
Increasing Rates of Lipoprotein(a) Testing in the United States from 2015-2024: An Analysis of 300 Million Individuals
Cohort study in peoplePopulations
AHA Scientific Sessions 2025 Abstract
Lipoprotein(a) Selectively Associates with Vulnerable Coronary Plaque Phenotypes in Comparison with Other Established Risk Markers
Cohort study of 547 peopleLipoprotein
AHA Scientific Sessions 2025 Abstract
Increased Prevalence of High Lipoprotein(a) in Autoimmune or Inflammatory Diseases: A Multi-Center Cohort Study
Cohort study of 49,503 peopleAutoimmune disease
AHA Scientific Sessions 2025 Abstract
Impact of Elevated Lipoprotein(a) on Cardiovascular Events in patients with premature ASCVD: A Nationally Representative Sample of US Medicare, Medicaid, and Commercial Enrollees
Cohort study of 97,775 peopleLipoprotein
AHA Scientific Sessions 2025 Abstract
Efficacy of Olpasiran by Apolipoprotein(a) Isoform Size: Insights from the OCEAN(a)-DOSE Trial
Randomized trial in 270 peopleInterventions
Thursday, October 23
ENDO 2025 Abstract
SAT-277 Efficacy And Safety Of Lipoprotein Apheresis In ASCVD Patients With Elevated Lipoprotein(a): A Multicenter Retrospective Study
Cohort study of 60 peopleInterventions
ENDO 2025 Abstract
SAT-260 Comparative Efficacy of Olpasiran and Zerlasiran in Reducing Lipoprotein(a) Levels: A Network Meta-Analysis of Clinical Trials
Meta-analysis of randomized trialsInterventions